J&J Vaccine Significantly Less Effective Against CCP Virus Variants, Study Suggests

J&J Vaccine Significantly Less Effective Against CCP Virus Variants, Study Suggests
A vial and syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken on Jan. 11, 2021. Dado Ruvic/Illustration/Reuters
Ivan Pentchoukov
Updated:

The Johnson & Johnson vaccine against COVID-19 is significantly less effective against variants, compared to the two other COVID-19 vaccines authorized for use in the United States, a pre-print study by scientists from the New York University School of Medicine suggests.

According to the paper’s summary, the antibodies elicited by the two-dose Pfizer–BioNTech and Moderna vaccines “showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants.” In contrast, the antibodies generated in response to the single-dose Johnson & Johnson vaccine had “significantly decreased neutralization.”

Ivan Pentchoukov
Ivan Pentchoukov
Author
Ivan is the national editor of The Epoch Times. He has reported for The Epoch Times on a variety of topics since 2011.
twitter
Related Topics